超过5%股东持股披露
NLS Pharmaceutics(NLSP)03-28 07:45
$NLS Pharmaceutics(NLSP)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0000929638-24-001262 Act: 34 Size: 75 KB 网页链接
NLS Pharmaceutics(NLSP)
0.188 %
简介：NLS Pharmaceutics Ltd.于2015年6月成立。 该公司是一家创新的生物制药公司，致力于发现和开发可改善罕见中枢神经系统疾病的改善生命的药物疗法。
公司网站：
公司地址：The Circle 6 8058 Zurich Switzerland
公司电话：41-44-5122150
| 今开：0.175 | 昨收：0.1869 |
| 最高：0.22 | 最低：0.175 |
| 涨停价： | 跌停价： |
| 总市值：8156421 |
NLS Pharmaceutics的热门讨论
财报披露
NLS Pharmaceutics(NLSP)06-07 05:05
$NLS Pharmaceutics(NLSP)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-050412 Act: 34 Size: 2 MB 网页链接
其他
NLS Pharmaceutics(NLSP)05-01 04:05
$NLS Pharmaceutics(NLSP)$ NT 20-F Notification of inability to timely file Form 20-F Accession Number: 0001213900-24-037801 Act: 34 Size: 22 KB 网页链接
财报披露
NLS Pharmaceutics(NLSP)04-16 04:05
$NLS Pharmaceutics(NLSP)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-032948 Act: 34 Size: 246 KB 网页链接
招股说明书
NLS Pharmaceutics(NLSP)05-30 18:05
$NLS Pharmaceutics(NLSP)$ F-1 Registration statement for certain foreign private issuers Accession Number: 0001213900-24-047585 Act: 33 Size: 262 KB 网页链接
财报披露
NLS Pharmaceutics(NLSP)05-28 21:15
$NLS Pharmaceutics(NLSP)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-046825 Act: 34 Size: 27 KB 网页链接
发行公告
NLS Pharmaceutics(NLSP)04-04 04:05
$NLS Pharmaceutics(NLSP)$ D Notice of Exempt Offering of Securities, item 06b Accession Number: 0001213900-24-029808 Act: 33 Size: 14 KB 网页链接
财报披露
NLS Pharmaceutics(NLSP)04-09 04:15
$NLS Pharmaceutics(NLSP)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-031179 Act: 34 Size: 10 KB 网页链接
财报披露
NLS Pharmaceutics(NLSP)04-20 05:25
$NLS Pharmaceutics(NLSP)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-034569 Act: 34 Size: 20 KB 网页链接
财报披露
NLS Pharmaceutics(NLSP)05-15 04:35
$NLS Pharmaceutics(NLSP)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-042968 Act: 34 Size: 48 KB 网页链接
NLS Pharmaceutics的最新讨论
讨论
鲜克有终72021-12-01 00:40
$NLS Pharmaceutics(NLSP)$ 日拱一卒无有尽，功不唐捐终入海查看全文
讨论
鲜克有终72021-11-30 23:38
讨论
冷枪手假亦真2021-07-15 21:24
讨论
大喜家的投顾观点2021-03-25 17:00
$NLS Pharmaceutics(NLSP)$什么时候开始起飞查看全文
讨论
冷枪手假亦真2021-03-12 22:21
![[赚大了]](http://js.xueqiu.com/ugc/images/face/emoji_06_money.png?v=1 "[赚大了]"){kind=small}
![[涨]](http://js.xueqiu.com/ugc/images/face/emoji_56_increase.png?v=1 "[涨]"){kind=small}
讨论
冷枪手假亦真2021-03-12 00:52
![[加]](http://js.xueqiu.com/ugc/images/face/emoji_52_plus.png?v=1 "[加]"){kind=small}
![[买]](http://js.xueqiu.com/ugc/images/face/emoji_54_buy.png?v=1 "[买]"){kind=small}
讨论
赚零花r2021-02-23 01:43
讨论
奥马哈买家俱乐部2021-01-29 23:21
$NLS Pharmaceutics(NLSP)$ 要破发的节奏啊，近一个月10块以下的新股上市没有不被爆炒的，你会是例外吗？查看全文
美股打新分析|NLS Pharmaceutics
紫藤财富故事2021-01-23 20:59
NLS Pharmaceutics（NLSP）
可申购券商：微牛证券
公司总部位于瑞士，NLS主要开发中枢神经系统疾病的治疗方法。
该公司目前的重点领域是开发用于治疗罕见的嗜睡症（过度或无法控制的白天嗜睡、嗜睡症）和注意力缺陷多动障碍（ADHD）的单分子药物。
NLSP的资本金很少，而且似乎在研...查看全文
NLS Pharmaceutics的公告
财报披露
$NLS Pharmaceutics(NLSP)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-051717 Act: 34 Size: 30 KB 网页链接
财报披露
$NLS Pharmaceutics(NLSP)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-050412 Act: 34 Size: 2 MB 网页链接
财报披露
$NLS Pharmaceutics(NLSP)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-048522 Act: 34 Size: 11 KB 网页链接
招股说明书
$NLS Pharmaceutics(NLSP)$ F-1 Registration statement for certain foreign private issuers Accession Number: 0001213900-24-047585 Act: 33 Size: 262 KB 网页链接
财报披露
$NLS Pharmaceutics(NLSP)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-046825 Act: 34 Size: 27 KB 网页链接
财报披露
$NLS Pharmaceutics(NLSP)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-046734 Act: 34 Size: 20 KB 网页链接
财报披露
$NLS Pharmaceutics(NLSP)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-045730 Act: 34 Size: 28 KB 网页链接
年度财报
$NLS Pharmaceutics(NLSP)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001213900-24-043570 Act: 34 Size: 8 MB 网页链接
财报披露
$NLS Pharmaceutics(NLSP)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-042968 Act: 34 Size: 48 KB 网页链接
其他
$NLS Pharmaceutics(NLSP)$ NT 20-F Notification of inability to timely file Form 20-F Accession Number: 0001213900-24-037801 Act: 34 Size: 22 KB 网页链接